Philip Reilly, MD, JD
Trained in internal medicine and clinical genetics, Dr. Reilly has deep expertise in launching companies to develop breakthrough therapies for rare genetic disorders. He was instrumental in creating two gene therapy companies, bluebird bio, for which he served as Chief Medical Officer and Voyager Therapeutics, which specializes in using the adeno-associated virus to treat disorders of the central nervous system. He also helped to launch Fulcrum Therapeutics, a company that focuses on gene regulation.
He is passionate about working with patient groups and helping to unite those suffering from rare diseases in order to foster a support network and potentially improve patient outcomes.
Dr. Reilly has authored or co-authored more than 100 articles in scholarly journals and has published seven books including most recently: Orphan: The Quest to Save Children with Rare Genetic Disorders. He serves on the Advisory Board to the Boston University School of Public Health and has served as a trustee emeritus of Cornell University, an Overseer of Weill Cornell Medical College.
Dr. Reilly holds an AB from Cornell University, a J.D. from Columbia University, and an MD from Yale University.